13F filer · CIK 1352851 ↗
Magnetar Financial LLC
You are looking at Q2 2023. See the latest, Q2 2026 →
Reported value
$4.56B
−11% on the quarter before
Positions
476
182 new · 303 sold out
Top 10
20.4%
of the value
Est. gain
+$99.2M
on stocks held all quarter
Est. return
+3.8%
on those stocks since Q1 2023
Positions as of Jun 30, 2023, from Magnetar Financial LLC's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 41% of the reported value, each sized by its share, colored by what the fund did with it since Q1 2023. Striped tiles are options.
Largest buys
Since Q1 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Triton Intl Ltd~$84.3MNew · 0.0% → 1.8%+1,012,911 shares
- Pdc Energy Inc~$76.6MNew · 0.0% → 1.7%+1,076,706 shares
- Arconic Corporation~$71.9MNew · 0.0% → 1.6%+2,430,347 shares
- Iveric Bio Inc~$65.6MNew · 0.0% → 1.4%+1,668,239 shares
- Life Storage Inc~$65.5MNew · 0.0% → 1.4%+492,471 shares
- Syneos Health Inc~$60.5MNew · 0.0% → 1.3%+1,434,586 shares
- Dice Therapeutics Inc~$53.7MNew · 0.0% → 1.2%+1,155,887 shares
- Amedisys Inc~$51.1MAdded · 0.0% → 1.1%+558,660 shares
- Regeneron Pharmaceuticals~$49.1MNew · 0.0% → 1.1%+68,320 shares
- National Instrs Corp~$48.5MNew · 0.0% → 1.1%+845,732 shares
Largest sells
Since Q1 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Shaw Communications Inc~$91.2MSold out · 1.8% → 0.0%−3,049,407 shares
- Mckesson Corp~$87.6MCut · 2.1% → 0.9%−205,065 shares
- Evoqua Water Technologies Co~$87.0MSold out · 1.7% → 0.0%−1,749,923 shares
- Eli Lilly~$83.4MCut · 1.8% → 0.9%−177,893 shares
- Gilead Sciences Inc~$77.8MSold out · 1.5% → 0.0%−937,496 shares
- Momentive Global Inc~$71.8MSold out · 1.4% → 0.0%−7,707,761 shares
- Qualtrics Intl Inc~$69.4MSold out · 1.4% → 0.0%−3,894,425 shares
- Oak Str Health Inc~$67.6MSold out · 1.3% → 0.0%−1,747,344 shares
- Encompass Health Corp~$53.3MCut · 2.0% → 1.7%−787,382 shares
- Becton Dickinson & Co~$52.3MSold out · 1.0% → 0.0%−211,424 shares
Holdings
As of Jun 30, 2023. Changes are in shares against Mar 31, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott LabsCOM · shares −3.6% · price +7.7% | 2.3% | $103.6M | +$7.4M | ||||||||
| Nuvasive IncCOM · shares +36% · price +0.7% | 2.2% | $100.9M | +$498,073 | ||||||||
| Albertsons Cos IncCOMMON STOCK · shares +21% · price +5.0% | 2.2% | $99.9M | +$3.9M | ||||||||
| Univar Solutions IncCOM · shares −1.0% · price +2.3% | 2.2% | $99.7M | +$2.3M | ||||||||
| Focus Finl Partners IncCOM CL A · shares +39% · price +1.2% | 2.1% | $95.0M | +$832,571 | ||||||||
| Aerojet Rocketdyne Hldgs IncCOM · shares −0.4% · price −2.3% | 2.0% | $92.8M | −$2.2M | ||||||||
| Pnm Res IncCOM · shares +2.0% · price −7.4% | 2.0% | $89.2M | −$6.9M | ||||||||
| Churchill Capital Corp ViiCOM CL A · shares −25% · price +1.8% | 1.9% | $85.7M | +$1.5M | ||||||||
| Triton Intl LtdCL A · shares New | 1.8% | $84.3M | — | ||||||||
| Radius Global Infrastrctre ICOM CL A · shares −1.7% · price +1.6% | 1.8% | $80.5M | +$1.2M | ||||||||
| Pdc Energy IncCOM · shares New | 1.7% | $76.6M | — | ||||||||
| Encompass Health CorpCOM · shares −41% · price +25.2% | 1.7% | $76.5M | +$15.4M | ||||||||
| Merck & Co IncCOM · shares −20% · price +8.5% | 1.7% | $75.5M | +$5.9M | ||||||||
| Arconic CorporationCOM · shares New | 1.6% | $71.9M | — | ||||||||
| Baxter Intl IncCOM · shares +20% · price +12.3% | 1.5% | $68.1M | +$6.2M | ||||||||
| Iveric Bio IncCOM · shares New | 1.4% | $65.6M | — | ||||||||
| Life Storage IncCOM · shares New | 1.4% | $65.5M | — | ||||||||
| Activision Blizzard IncCOM · shares −5.4% · price −1.5% | 1.4% | $63.9M | −$977,254 | ||||||||
| Seagen IncCOM · shares +16% · price −4.9% | 1.4% | $63.2M | −$2.8M | ||||||||
| Gsk PlcSPONSORED ADR · shares +17% · price +0.2% | 1.4% | $63.0M | +$90,924 | ||||||||
| Horizon Therapeutics Pub LSHS · shares −17% · price −5.8% | 1.4% | $62.7M | −$3.8M | ||||||||
| Syneos Health IncCL A · shares New | 1.3% | $60.5M | — | ||||||||
| Elanco Animal Health IncCOM · shares +108% · price +7.0% | 1.3% | $59.8M | +$1.9M | ||||||||
| The Cigna GroupCOM · shares −21% · price +9.8% | 1.3% | $59.1M | +$5.3M | ||||||||
| Forgerock IncCL A · shares +0.7% · price −0.3% | 1.3% | $58.8M | −$170,699 | ||||||||
| Total · 476 positions | 100% | $4.56B | +$99.2M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2023 to Q2 2023: 263 stocks held throughout, up $99.2M (+3.8%).
- Encompass Health Corp+$15.4M+25%
- Eli Lilly+$11.5M+37%
- Abbott Labs+$7.4M+8%
- Vmware Inc+$7.1M+15%
- Mckesson Corp+$6.5M+20%
- Brooge Energy Ltd−$3.3M−22%
- Thermo Fisher Scientific Inc−$3.6M−9%
- Humana Inc−$3.8M−8%
- Horizon Therapeutics Pub L−$3.8M−6%
- Pnm Res Inc−$6.9M−7%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $10.96B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $9.84B−4% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $10.21B−38% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $16.50B−20% | SEC ↗ |
| Q2 2025 | Aug 12, 2025 | $20.65B+171% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $7.61B+75% | SEC ↗ |
| Q4 2024 | Feb 11, 2025 | $4.36B−6% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $4.62B−4% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $4.80B+7% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $4.47B+13% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $3.94B+1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $3.92B−14% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $4.56B−11% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $5.13B−13% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $5.91B−18% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.21B−25% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $9.67B+3% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $9.37B−6% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $9.96B+1% | SEC ↗ |
| Q3 2021 | Jan 14, 2022 (amended) | $9.82B−7% | SEC ↗ |
| Q2 2021 | Aug 6, 2021 | $10.56B+2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $10.40B+47% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $7.08B+25% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $5.66B+67% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $3.39B−18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $4.15B−13% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $4.79B+22% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $3.93B−21% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $5.00B+29% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $3.89B−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $4.08B−26% | SEC ↗ |
| Q3 2018 | Feb 14, 2019 (amended) | $5.54B−16% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 (amended) | $6.56B+13% | SEC ↗ |
| Q1 2018 | May 15, 2018 (amended) | $5.80B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 (amended) | $5.62B+2% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 (amended) | $5.52B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 (amended) | $6.52B−7% | SEC ↗ |
| Q1 2017 | May 15, 2017 (amended) | $7.02B+1,897% | SEC ↗ |
| Q4 2016 | Aug 14, 2017 (amended) | $351.5M−95% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 (amended) | $7.03B+17% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 (amended) | $6.02B−7% | SEC ↗ |
| Q1 2016 | May 16, 2016 (amended) | $6.49B | SEC ↗ |